Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) saw an uptick in trading volume on Thursday . 239,783 shares were traded during mid-day trading, a decline of 2% from the previous session’s volume of 245,352 shares.The stock last traded at $14.51 and had previously closed at $13.67.

Several brokerages have commented on ADMS. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $44.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. Cowen and Company reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Thursday, May 12th. Mizuho upgraded shares of Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 price target for the company in a report on Thursday, June 16th. Noble Financial assumed coverage on shares of Adamas Pharmaceuticals in a report on Friday, June 17th. They issued a “buy” rating and a $25.00 price target for the company. Finally, JMP Securities reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a report on Wednesday, June 15th. Two analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $32.00.

The company has a 50-day moving average of $14.22 and a 200 day moving average of $15.29. The firm’s market capitalization is $330.47 million.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP increased its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned approximately 0.38% of Adamas Pharmaceuticals worth $1,966,000 at the end of the most recent reporting period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.